Margaret Sullivan Pepe | Academic Influence

Margaret Sullivan Pepe's AcademicInfluence.com Rankings

Margaret Sullivan Pepe

Mathematics

#5463

World Rank

#7685

Historical Rank

Statistics

#384

World Rank

#452

Historical Rank

Measure Theory

#950

World Rank

#1237

Historical Rank

mathematics Degrees

Download Badge

Mathematics

Margaret Sullivan Pepe's Degrees

PhD Biostatistics Trinity College Dublin
Masters Statistics Trinity College Dublin
Bachelors Mathematics Trinity College Dublin

Similar Degrees You Can Earn

Best Online Bachelor's in Math 2025

Why Is Margaret Sullivan Pepe Influential?

(Suggest an Edit or Addition)

According to Wikipedia, Margaret Patricia O'Sullivan Pepe is an Irish biostatistician specializing in the evaluation of tests and biomarkers for disease screening. She is a professor of biostatistics at the University of Washington School of Public Health and a researcher at the Fred Hutchinson Cancer Research Center.

(See a Problem?)

Margaret Sullivan Pepe's Published Works

Number of citations in a given year to any of this author's works

Total number of citations to an author for the works they published in a given year. This highlights publication of the most important work(s) by the author

Published Works

Time‐Dependent ROC Curves for Censored Survival Data and a Diagnostic Marker (2000) (2149)
Predicting obesity in young adulthood from childhood and parental obesity. (1997) (1702)
The Statistical Evaluation of Medical Tests for Classification and Prediction (2003) (1621)
Phases of biomarker development for early detection of cancer. (2001) (1509)
Continual reassessment method: a practical design for phase 1 clinical trials in cancer. (1990) (1405)
Limitations of the odds ratio in gauging the performance of a diagnostic, prognostic, or screening marker. (2004) (1234)
Intermittent administration of inhaled tobramycin in patients with cystic fibrosis. Cystic Fibrosis Inhaled Tobramycin Study Group. (1999) (1094)
Pivotal Evaluation of the Accuracy of a Biomarker Used for Classification or Prediction: Standards for Study Design (2008) (608)
Kaplan-Meier, marginal or conditional probability curves in summarizing competing risks failure time data? (1993) (591)
Early Adiposity Rebound and the Risk of Adult Obesity (1998) (541)
Diagnostic concordance among pathologists interpreting breast biopsy specimens. (2015) (487)
Methotrexate and cyclosporine versus cyclosporine alone for prophylaxis of graft-versus-host disease in patients given HLA-identical marrow grafts for leukemia: long-term follow-up of a controlled trial. (1989) (428)
Acute graft-versus-host disease: analysis of risk factors after allogeneic marrow transplantation and prophylaxis with cyclosporine and methotrexate. (1992) (399)
A cautionary note on inference for marginal regression models with longitudinal data and general correlated response data (1994) (362)
Gender gap in cystic fibrosis mortality. (1997) (351)
Partial AUC Estimation and Regression (2003) (329)
Net reclassification indices for evaluating risk prediction instruments: a critical review. (2014) (311)
Some Graphical Displays and Marginal Regression Analyses for Recurrent Failure Times and Time Dependent Covariates (1993) (297)
Comparisons of Predictive Values of Binary Medical Diagnostic Tests for Paired Designs (2000) (297)
Weighted Kaplan-Meier statistics: a class of distance tests for censored survival data. (1989) (286)
Combining diagnostic test results to increase accuracy. (2000) (285)
Integrating the predictiveness of a marker with its performance as a classifier. (2007) (283)
A data-analytic strategy for protein biomarker discovery: profiling of high-dimensional proteomic data for cancer detection. (2003) (279)
Defining a pulmonary exacerbation in cystic fibrosis. (2001) (276)
Inactivation of p16, RUNX3, and HPP1 occurs early in Barrett's-associated neoplastic progression and predicts progression risk (2005) (270)
Estimation and Comparison of Receiver Operating Characteristic Curves (2009) (266)
Combining Predictors for Classification Using the Area under the Receiver Operating Characteristic Curve (2006) (252)
Combining Several Screening Tests: Optimality of the Risk Score (2002) (249)
An Interpretation for the ROC Curve and Inference Using GLM Procedures (2000) (242)
Inference for Events with Dependent Risks in Multiple Endpoint Studies (1991) (240)
A mean score method for missing and auxiliary covariate data in regression models (1995) (236)
Selecting Differentially Expressed Genes from Microarray Experiments (2003) (233)
Marrow transplantation from unrelated donors for treatment of hematologic malignancies: effect of mismatching for one HLA locus. (1993) (232)
Using a combination of reference tests to assess the accuracy of a new diagnostic test. (1999) (231)
Assessing the Value of Risk Predictions by Using Risk Stratification Tables (2008) (230)
Testing for improvement in prediction model performance (2013) (210)
Distribution-free ROC analysis using binary regression techniques. (2002) (209)
A Nonparametric Method for Dealing with Mismeasured Covariate Data (1991) (203)
Receiver Operating Characteristic Methodology (2000) (200)
Three approaches to regression analysis of receiver operating characteristic curves for continuous test results. (1998) (192)
Adjusting for covariates in studies of diagnostic, screening, or prognostic markers: an old concept in a new setting. (2008) (191)
Inference using surrogate outcome data and a validation sample (1992) (185)
Pathologists’ diagnosis of invasive melanoma and melanocytic proliferations: observer accuracy and reproducibility study (2017) (180)
Auxiliary covariate data in failure time regression (1995) (176)
Insights into latent class analysis of diagnostic test performance. (2007) (172)
Surrogate and auxiliary endpoints in clinical trials, with potential applications in cancer and AIDS research. (1994) (166)
Do erythropoietin receptors on cancer cells explain unexpected clinical findings? (2006) (154)
Impact of patient weight on non-relapse mortality after marrow transplantation. (1995) (142)
Measuring the Performance of Markers for Guiding Treatment Decisions (2011) (142)
A regression modelling framework for receiver operating characteristic curves in medical diagnostic testing (1997) (135)
Response to tetanus toxoid immunization after allogeneic bone marrow transplantation. (1990) (131)
Gestational diabetes and the risk of offspring obesity. (1998) (130)
Accommodating Covariates in Receiver Operating Characteristic Analysis (2009) (128)
The Net Reclassification Index (NRI): A Misleading Measure of Prediction Improvement Even with Independent Test Data Sets (2015) (127)
Comments on ‘Evaluating the added predictive ability of a new marker: From area under the ROC curve to reclassification and beyond’ by M. J. Pencina et al., Statistics in Medicine (DOI: 10.1002/sim.2929) (2008) (120)
A comparison of peak sputum tobramycin concentration in patients with cystic fibrosis using jet and ultrasonic nebulizer systems. Aerosolized Tobramycin Study Group. (1997) (117)
Increased risk of infection in marrow transplant patients receiving methylprednisolone for graft-versus-host disease prevention. (1994) (114)
Pathologists’ diagnosis of invasive melanoma and melanocytic proliferations: observer accuracy and reproducibility study (2017) (114)
Dietary fat and breast cancer: a quantitative assessment of the epidemiological literature and a discussion of methodological issues. (1989) (113)
Comparing the predictive values of diagnostic tests: sample size and analysis for paired study designs (2006) (112)
Semiparametric estimation of regression quantiles with application to standardizing weight for height and age in US children (1999) (111)
Problems with risk reclassification methods for evaluating prediction models. (2011) (110)
A marginal regression modelling framework for evaluating medical diagnostic tests. (1997) (110)
Incorporating the Time Dimension in Receiver Operating Characteristic Curves: A Case Study of Prostate Cancer (1999) (106)
Evaluating Markers for Selecting a Patient's Treatment (2004) (103)
What role for prednisone in prevention of acute graft-versus-host disease in patients undergoing marrow transplants ? (1990) (102)
Graft‐versus‐host disease prevention by methotrexate combined with cyclosporin compared to methotrexate alone in patients given marrow grafts for severe aplastic anaemia: long‐term follow‐up of a controlled trial (1989) (102)
Adjusting for covariate effects on classification accuracy using the covariate-adjusted receiver operating characteristic curve. (2009) (102)
Weighted Kaplan‐Meier Statistics: Large Sample and Optimality Considerations (1991) (93)
Combining biomarkers to detect disease with application to prostate cancer. (2003) (93)
Auxiliary outcome data and the mean score method (1994) (93)
Previous donor pregnancy as a risk factor for acute graft‐versus‐host disease in patients with aplastic anaemia treated by allogeneic marrow transplantation (1990) (90)
Semiparametric Receiver Operating Characteristic Analysis to Evaluate Biomarkers for Disease (2002) (88)
Statistical description of interrater variability in ordinal ratings (2000) (87)
The sensitivity and specificity of markers for event times. (2005) (87)
Summarizing data on survival, relapse, and chronic graft‐versus‐host disease after bone marrow transplantation: motivation for and description of new methods (1993) (86)
Accommodating Covariates in ROC Analysis. (2009) (86)
Sample size calculations for comparative studies of medical tests for detecting presence of disease (2002) (86)
Comparing disease screening tests when true disease status is ascertained only for screen positives. (2001) (82)
Further results on covariate measurement errors in cohort studies with time to response data. (1989) (82)
Improvement in rejection, engraftment rate and survival without increase in graft‐versus‐host disease by high marrow cell dose in patients transplanted for aplastic anaemia (1988) (82)
Semiparametric Regression for the Area Under the Receiver Operating Characteristic Curve (2003) (81)
Endoscopic ultrasound, positron emission tomography, and computerized tomography for lung cancer. (2003) (80)
Gauging the performance of SNPs, biomarkers, and clinical factors for predicting risk of breast cancer. (2008) (77)
Comparison of fractionated to single-dose total body irradiation in conditioning canine littermates for DLA-identical marrow grafts. (1989) (74)
Net risk reclassification p values: valid or misleading? (2014) (74)
Standardizing Diagnostic Markers to Evaluate and Compare Their Performance (2005) (73)
A qualifier Q for the survival function to describe the prevalence of a transient condition. (1991) (70)
Assessing accuracy of a continuous screening test in the presence of verification bias (2005) (67)
Immunosuppressive therapy of aplastic anemia: results of a prospective, randomized trial of antithymocyte globulin (ATG), methylprednisolone, and oxymetholone to ATG, very high-dose methylprednisolone, and oxymetholone. (1992) (67)
Serum tumor necrosis factor alpha associated with acute graft-versus-host disease in humans. (1990) (66)
Using the ROC curve for gauging treatment effect in clinical trials (2006) (66)
Evaluating the ROC performance of markers for future events (2008) (66)
Measures to Summarize and Compare the Predictive Capacity of Markers (2009) (64)
Matching in Studies of Classification Accuracy: Implications for Analysis, Efficiency, and Assessment of Incremental Value (2008) (62)
Effect of choice of reference equation on analysis of pulmonary function in cystic fibrosis patients * (2001) (62)
Estimating disease prevalence in two-phase studies. (2003) (61)
Marrow toxicity of fractionated vs. single dose total body irradiation is identical in a canine model. (1993) (61)
Cumulative incidence of secondary solid malignant tumors in aplastic anemia patients given marrow grafts after conditioning with chemotherapy alone. (1992) (59)
Evaluating technologies for classification and prediction in medicine (2005) (57)
Nutritional effects of long-term gastrostomy feedings in children with cystic fibrosis. (1999) (56)
FK‐506 AND METHOTREXATE PREVENT GRAFT‐VERSUS-HOST DISEASE IN DOGS GIVEN 9.2 Gy TOTAL BODY IRRADIATION AND MARROW GRAFTS FROM UNRELATED DOG LEUKOCYTE ANTIGEN‐NONIDENTICAL DONORS (1993) (55)
Modeling Partly Conditional Means with Longitudinal Data (1997) (55)
Abnormalities of pulmonary function tests after marrow transplantation predict nonrelapse mortality. (1995) (53)
Early-Phase Studies of Biomarkers: What Target Sensitivity and Specificity Values Might Confer Clinical Utility? (2016) (53)
An Approach to Evaluating and Comparing Biomarkers for Patient Treatment Selection (2014) (51)
Quantifying and comparing the predictive accuracy of continuous prognostic factors for binary outcomes. (2004) (50)
Estimating the capacity for improvement in risk prediction with a marker. (2008) (50)
Methods for Evaluating Prediction Performance of Biomarkers and Tests (2013) (50)
Does the Net Reclassification Improvement Help Us Evaluate Models and Markers? (2014) (50)
Two-stage experimental designs : early stopping with a negative result (1992) (49)
Effects of repetitive use and cleaning techniques of disposable jet nebulizers on aerosol generation. (1998) (48)
A Parametric ROC Model‐Based Approach for Evaluating the Predictiveness of Continuous Markers in Case–Control Studies (2009) (47)
Time-Dependent Predictive Values of Prognostic Biomarkers With Failure Time Outcome (2008) (46)
Variability in Pathologists' Interpretations of Individual Breast Biopsy Slides: A Population Perspective (2016) (46)
The Early Detection Research Network's Specimen reference sets: paving the way for rapid evaluation of potential biomarkers. (2013) (45)
Estimating and comparing univariate associations with application to the prediction of adult obesity. (1999) (43)
Development of a diagnostic test set to assess agreement in breast pathology: practical application of the Guidelines for Reporting Reliability and Agreement Studies (GRRAS) (2013) (43)
Regression modelling of diagnostic likelihood ratios for the evaluation of medical diagnostic tests. (1998) (43)
The Potential of Genes and Other Markers to Inform about Risk (2010) (42)
Long-term follow-up of a controlled trial comparing a combination of methotrexate plus cyclosporine with cyclosporine alone for prophylaxis of graft-versus-host disease in patients administered HLA-identical marrow grafts for leukemia [letter] (1992) (41)
The effect of exposure variance and exposure measurement error on study sample size: implications for the design of epidemiologic studies. (1994) (40)
Assessing risk prediction models in case–control studies using semiparametric and nonparametric methods (2010) (39)
Biases introduced by choosing controls to match risk factors of cases in biomarker research. (2012) (39)
Conditional estimation of sensitivity and specificity from a phase 2 biomarker study allowing early termination for futility (2009) (39)
Estimating the receiver operating characteristic curve in studies that match controls to cases on covariates. (2013) (38)
Limitations of the Odds Ratio in Gauging the Performance of a Diagnostic or Prognostic Marker (2004) (36)
A pilot study of low‐dose cyclosporin for graft‐versus‐host prophylaxis in marrow transplantation (1992) (36)
Improving the Quality of Biomarker Discovery Research: The Right Samples and Enough of Them (2015) (36)
What role for prednisone in prevention of acute graft-versus-host disease in patients undergoing marrow transplants? (1990) (35)
Quantifying and comparing the accuracy of binary biomarkers when predicting a failure time outcome (2004) (35)
Prevalence of clinically relevant bacteremia after upper gastrointestinal endoscopy in bone marrow transplant recipients. (1990) (35)
Further insight into the incremental value of new markers: the interpretation of performance measures and the importance of clinical context. (2012) (35)
Methotrexate and cyclosporine for graft-vs.-host disease prevention: what length of therapy with cyclosporine? (1997) (34)
The relationship between hot-deck multiple imputation and weighted likelihood. (1997) (33)
Conditional estimation after a two‐stage diagnostic biomarker study that allows early termination for futility (2012) (31)
The diagnostic challenge of low-grade ductal carcinoma in situ. (2017) (30)
Evaluation of 12 strategies for obtaining second opinions to improve interpretation of breast histopathology: simulation study (2016) (29)
A Randomized Study Comparing Digital Imaging to Traditional Glass Slide Microscopy for Breast Biopsy and Cancer Diagnosis (2017) (29)
The optimal ratio of cases to controls for estimating the classification accuracy of a biomarker. (2005) (28)
The Fundamental Difficulty With Evaluating the Accuracy of Biomarkers for Guiding Treatment. (2015) (27)
Concordance and Reproducibility of Melanoma Staging According to the 7th vs 8th Edition of the AJCC Cancer Staging Manual (2018) (26)
Assessment of Second-Opinion Strategies for Diagnoses of Cutaneous Melanocytic Lesions (2019) (26)
Modelling prevalence of a condition: chronic graft-versus-host disease after bone marrow transplantation. (1997) (26)
Commentary: Reporting standards are needed for evaluations of risk reclassification. (2011) (25)
Cytomegalovirus infection after marrow transplantation for aplastic anemia. (1990) (25)
Declining lymphocyte counts following cytomegalovirus (CMV) infection are associated with fatal CMV disease in bone marrow transplant patients. (1993) (25)
A Framework for Evaluating Markers Used to Select Patient Treatment (2014) (24)
Improving biomarker identification with better designs and reporting. (2011) (24)
Adjusting for Covariate Effects on Classification Accuracy Using the Covariate-Adjusted ROC Curve (2006) (24)
Graft-versus-host disease prophylaxis with methotrexate/cyclosporine in children with severe aplastic anemia treated with cyclophosphamide and HLA-identical marrow grafts [letter] (1991) (24)
Activation signals leading to proliferation of normal and leukemic CD3+ large granular lymphocytes. (1991) (23)
Second opinion strategies in breast pathology: a decision analysis addressing over-treatment, under-treatment, and care costs (2017) (23)
Letter by Pepe et al regarding article, "Use and misuse of the receiver operating characteristic curve in risk prediction". (2007) (22)
Pathologist characteristics associated with accuracy and reproducibility of melanocytic skin lesion interpretation (2018) (22)
Prediction Using Partly Conditional Time‐Varying Coefficients Regression Models (1999) (22)
Identifying target populations for screening or not screening using logic regression (2005) (22)
Estimating the diagnostic likelihood ratio of a continuous marker. (2011) (21)
Biomarker evaluation and comparison using the controls as a reference population. (2009) (21)
Partially Supervised Learning Using an EM‐Boosting Algorithm (2004) (20)
Factors predicting chronic graft-versus-host disease and survival after marrow transplantation for aplastic anemia. (1989) (20)
Combining Predictors for Classification Using the Area Under the ROC Curve (2004) (19)
Methods for Assessing Improvement in Specificity When a Biomarker is Combined With a Standard Screening Test (2009) (19)
Semiparametric methods for evaluating risk prediction markers in case-control studies. (2009) (18)
Improving risk classification of critical illness with biomarkers: a simulation study. (2013) (18)
Diagnostic Reproducibility: What Happens When the Same Pathologist Interprets the Same Breast Biopsy Specimen at Two Points in Time? (2017) (17)
Monitoring of a pilot toxicity study with two adverse outcomes. (1994) (16)
Long-term follow-up of three controlled trials comparing cyclosporine versus methotrexate for graft-versus-host disease prevention in patients given marrow grafts for leukemia [letter] (1992) (16)
Adopting nested case–control quota sampling designs for the evaluation of risk markers (2013) (16)
Long-term follow-up of a controlled trial comparing a combination of methotrexate plus cyclosporine with cyclosporine alone for prophylaxis of graft-versus-host disease in patients administered HLA-identical marrow grafts for leukemia. (1992) (16)
Design of a study to improve accuracy in reading mammograms. (1997) (16)
A framework for evaluating diagnostic discordance in pathology discovered during research studies. (2014) (16)
The Net Reclassification Index (NRI): a Misleading Measure of Prediction Improvement with Miscalibrated or Overfit Models (2013) (16)
Assessing the Accuracy of a New Diagnostic Test When a Gold Standard Does Not Exist (1998) (15)
Association Between Benign Breast Disease in African American and White American Women and Subsequent Triple-Negative Breast Cancer (2017) (14)
Joint Modeling, Covariate Adjustment, and Interaction: Contrasting Notions in Risk Prediction Models and Risk Prediction Performance (2011) (14)
Development and evaluation of classifiers. (2007) (14)
Contrasting Two Frameworks for ROC Analysis of Ordinal Ratings (2010) (14)
Adding Rigor to Biomarker Evaluations—EDRN Experience (2020) (14)
Construction and Analysis of the NCI-EDRN Breast Cancer Reference Set for Circulating Markers of Disease (2014) (13)
Designing a study to evaluate the benefit of a biomarker for selecting patient treatment (2015) (12)
Gamma radiation of blood products prevents rejection of subsequent DLA-identical marrow grafts. Tolerance versus abrogation of sensitization to non-DLA antigens. (1996) (12)
PHARMACOLOGIC, TOXICOLOGIC, AND MARROW TRANSPLANTATION STUDIES IN DOGS GIVEN SUCCINYL ACETONE (1992) (12)
Graft-versus-host disease prophylaxis with methotrexate/cyclosporine in children with severe aplastic anemia treated with cyclophosphamide and HLA-identical marrow grafts. (1991) (11)
Discordant Interpretations of Breast Biopsy Specimens by Pathologists--Reply. (2015) (10)
Semiparametric methods for evaluating the covariate‐specific predictiveness of continuous markers in matched case–control studies (2010) (10)
Statistical inference for net benefit measures in biomarker validation studies (2019) (10)
Standardizing Markers to Evaluate and Compare their Performances (2005) (9)
Insights into Latent Class Analysis (2005) (9)
Logistic regression analysis with standardized markers (2013) (9)
The Net Reclassification Index (NRI): A Misleading Measure of Prediction Improvement Even with Independent Test Data Sets (2014) (8)
Estimating improvement in prediction with matched case–control designs (2013) (8)
Serum transferrin receptor is a marker of iron deficiency in patients included in programs for preoperative autologous blood donation. (2002) (7)
Combining biomarkers by maximizing the true positive rate for a fixed false positive rate (2019) (7)
Biomarker Evaluation Using the Controls as a Reference Population (2007) (7)
Statistical Methods for Evaluating and Comparing Biomarkers for Patient Treatment Selection (2013) (5)
Long-term follow-up of three controlled trials comparing cyclosporine versus methotrexate for graft-versus-host disease prevention in patients given marrow grafts for leukemia. (1992) (5)
Re: "Clinical usefulness of the Framingham cardiovascular risk profile beyond its statistical performance: the Tehran Lipid and Glucose Study". (2013) (5)
AComparison ofPeakSputum Tobramycin Concentration inPatients WithCystic Fibrosis Using Jetand Ultrasonic Nebulizer Systems (2015) (4)
Net Reclassification Index: a Misleading Measure of Prediction Improvement (2013) (4)
Succinyl acetone plus methotrexate as graft-versus-host disease prophylaxis in DLA-haploidentical canine littermate marrow grafts. (1992) (4)
Recommendation to use exact P-values in biomarker discovery research in place of approximate P-values. (2018) (4)
What role for 15-deoxyspergualin in enhancing engraftment of unrelated, histoincompatible canine marrow grafts and preventing graft-versus-host disease? (1993) (4)
Effect of recombinant canine stem cell factor, a c-kit ligand, on hematopoietic recovery after DLA-identical littermate marrow transplants in dogs. (1997) (4)
Splenectomy does not enhance engraftment of DLA-nonidentical marrow transplants. (1993) (3)
12 Evaluating diagnostic tests in public health (2000) (3)
Semiparametric and nonparametric methods for evaluating risk prediction markers in case-control studies (2008) (3)
Rejoinder to Nancy Cook's Comment on "Measures to Summarize and Compare the Predictive Capacity of Markers" (2010) (2)
Risk Factors for Invasive Haemophilus influenzae Disease among Children 2-16 Years of Age in the Vaccine Era, Switzerland 1991-1993 (2005) (1)
Histopathological diagnosis of cutaneous melanocytic lesions: blinded and nonblinded second opinions offer similar improvement in diagnostic accuracy (2022) (1)
Semiparametric Least Squares Based Estimation of the Receiver Operating Characteristic ( ROC ) Curve (2005) (1)
LOGISTIC REGRESSION ANALYSIS WITH STANDARDIZED MARKERS. (2013) (1)
Association of Second-Opinion Strategies in the Histopathologic Diagnosis of Cutaneous Melanocytic Lesions With Diagnostic Accuracy and Population-Level Costs. (2021) (1)
Discussion of Briggs and Zaretzki Article (2007) (1)
A Practical Multifaceted Approach to Selecting Differentially Expressed Genes (2007) (1)
Calibrating Observed Differential Gene Expression for the Multiplicity of Genes on the Array (2004) (0)
Asymptotic theory of the estimated partial likelihood (1993) (0)
Estimating residual noise in the auditory brain-stem response. (1995) (0)
disease in patients undergoing marrow transplants? What role for prednisone in prevention of acute graft-versus-host (2011) (0)
Series 1-22-2008 Accommodating Covariates in ROC Analysis (2017) (0)
Diagnostic likelihood ratio (2018) (0)
chemotherapy alone (letter; comment) anemia patients given marrow grafts after conditioning with Cumulative incidence of secondary solid malignant tumors in aplastic (2011) (0)
True positive fraction (2018) (0)
True negative fraction (2018) (0)
Series 1-7-2005 Insights into Latent Class Analysis (2017) (0)
Construction and Analysis of the NCI-EDRN Breast Cancer Reference Set for Circulating Markers of Disease Running Title : Breast Cancer Reference Set for Circulating Markers (2014) (0)
Estimating improvement in prediction with matched case–control designs (2013) (0)
Auxiliary covariate measurement problem in failure time regression (1993) (0)
Abstract 866: Identification of novel early detection candidate protein biomarkers for ER+/PR+ invasive ductal breast carcinoma using pre-clinical plasma from the Women's Health Initiative Observational Study (2014) (0)
marker variables included in markers, and columns are as for b. Returned whether bootstrap sampling is specified or not (nobstrap). (2009) (0)
Series 10-1-1998 Assessing the Accuracy of a New Diagnostic Test When a Gold Standard Does Not Exist (2017) (0)
Abstract 713: Proteomic early detection biomarkers for ER+ breast cancer to improve mammography screening (2017) (0)
Series 3-28-2012 Testing for improvement in prediction model performance (2017) (0)
Adopting nested case–control quota sampling designs for the evaluation of risk markers (2013) (0)
cyclophosphamide and HLA-identical marrow grafts (letter) in children with severe aplastic anemia treated with Graft-versus-host disease prophylaxis with methotrexate/cyclosporine (2011) (0)
Series 6-27-2011 When Does Combining Markers Improve Classification Performance and What Are Implications for Practice ? (2017) (0)
P7 Quantifying the Potential Impact of Second Opinion Strategies for Improving Pathologic Interpretation of Breast Biopsy Specimens (2018) (0)
RISK FACTORS FOR ACUTE GRAFT-VERSUS-HOST DISEASE ASSOCIATED WITH CYCLOSPORINE AND METHOTREXATE PROPHYLAXIS (2003) (0)
810: IMPROVING RISK CLASSIFICATION OF CRITICAL ILLNESS WITH BIOMARKERS (2012) (0)
Abstract P4-02-05: A blinded multicenter phase II study of a panel of plasma biomarkers for the detection of triple negative breast cancer (2015) (0)
[Action of complement in normal pregnancy and gestosis]. (1979) (0)

This paper list is powered by the following services:

Other Resources About Margaret Sullivan Pepe

en.wikipedia.org

What Schools Are Affiliated With Margaret Sullivan Pepe?

Margaret Sullivan Pepe is affiliated with the following schools: